Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Androgen-responsive and nonresponsive prostate cancer cells present a distinct glycolytic metabolism profile
Cátia V. Vaz, Marco G. Alves, Ricardo Marques, et al.
The International Journal of Biochemistry & Cell Biology (2012) Vol. 44, Iss. 11, pp. 2077-2084
Closed Access | Times Cited: 84

Showing 1-25 of 84 citing articles:

Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches
Theodoros Karantanos, Paul G. Corn, Timothy C. Thompson
Oncogene (2013) Vol. 32, Iss. 49, pp. 5501-5511
Open Access | Times Cited: 756
High‐energy diets may induce a pre‐diabetic state altering testicular glycolytic metabolic profile and male reproductive parameters
Luís Rato, Marco G. Alves, Tânia R. Dias, et al.
Andrology (2013) Vol. 1, Iss. 3, pp. 495-504
Closed Access | Times Cited: 164
The Warburg Effect Revisited—Lesson from the Sertoli Cell
Pedro F. Oliveira, Ana D. Martins, Ana C. Moreira, et al.
Medicinal Research Reviews (2014) Vol. 35, Iss. 1, pp. 126-151
Open Access | Times Cited: 163
GLUT1 regulates cell glycolysis and proliferation in prostate cancer
Hengjun Xiao, Jun Wang, Weixin Yan, et al.
The Prostate (2017) Vol. 78, Iss. 2, pp. 86-94
Open Access | Times Cited: 144
Metabolic Plasticity in Chemotherapy Resistance
María Andrea Desbats, Isabella Giacomini, Tommaso Prayer‐Galetti, et al.
Frontiers in Oncology (2020) Vol. 10
Open Access | Times Cited: 135
Biomarker Discovery in Human Prostate Cancer: an Update in Metabolomics Studies
Ana Rita Lima, Maria de Lourdes Bastos, Márcia Carvalho, et al.
Translational Oncology (2016) Vol. 9, Iss. 4, pp. 357-370
Open Access | Times Cited: 126
Organ-Specific Cancer Metabolism and Its Potential for Therapy
Ilaria Elia, Roberta Schmieder, Stefan Christen, et al.
Handbook of experimental pharmacology (2015), pp. 321-353
Open Access | Times Cited: 108
TheMCT4Gene: A Novel, Potential Target for Therapy of Advanced Prostate Cancer
Stephen Yiu Chuen Choi, Hui Xue, Rebecca Wu, et al.
Clinical Cancer Research (2016) Vol. 22, Iss. 11, pp. 2721-2733
Open Access | Times Cited: 88
Metabolic adaptations in prostate cancer
Mikel Pujana-Vaquerizo, Laura Bozal-Basterra, Arkaitz Carracedo
British Journal of Cancer (2024) Vol. 131, Iss. 8, pp. 1250-1262
Open Access | Times Cited: 12
The progression from a lower to a higher invasive stage of bladder cancer is associated with severe alterations in glucose and pyruvate metabolism
Vanessa R. Conde, Pedro F. Oliveira, Ana R. Nunes, et al.
Experimental Cell Research (2015) Vol. 335, Iss. 1, pp. 91-98
Open Access | Times Cited: 87
Inhibition of O-GlcNAc transferase activity reprograms prostate cancer cell metabolism
Harri M. Itkonen, Saurabh S. Gorad, Damien Y. Duveau, et al.
Oncotarget (2016) Vol. 7, Iss. 11, pp. 12464-12476
Open Access | Times Cited: 82
GLUT1 protects prostate cancer cells from glucose deprivation-induced oxidative stress
Pedro González‐Menéndez, David Hevia, Rebeca Alonso‐Arias, et al.
Redox Biology (2018) Vol. 17, pp. 112-127
Open Access | Times Cited: 76
The dark side of glucose transporters in prostate cancer: Are they a new feature to characterize carcinomas?
Pedro González‐Menéndez, David Hevia, Juan C. Mayo, et al.
International Journal of Cancer (2017) Vol. 142, Iss. 12, pp. 2414-2424
Open Access | Times Cited: 73
Metabolic Differences in Glutamine Utilization Lead to Metabolic Vulnerabilities in Prostate Cancer
Niki M. Zacharias, Christopher McCullough, Sriram S. Shanmugavelandy, et al.
Scientific Reports (2017) Vol. 7, Iss. 1
Open Access | Times Cited: 64
GLUT1 is an AR target contributing to tumor growth and glycolysis in castration-resistant and enzalutamide-resistant prostate cancers
Jun Wang, Wenhao Xu, Beihe Wang, et al.
Cancer Letters (2020) Vol. 485, pp. 45-55
Closed Access | Times Cited: 56
Prostate cancer-derived extracellular vesicles metabolic biomarkers: Emerging roles for diagnosis and prognosis
Mahmoud Assem Hamed, Valerie C. Wasinger, Qi Wang, et al.
Journal of Controlled Release (2024) Vol. 371, pp. 126-145
Open Access | Times Cited: 7
Androgens enhance the glycolytic metabolism and lactate export in prostate cancer cells by modulating the expression of GLUT1, GLUT3, PFK, LDH and MCT4 genes
Cátia V. Vaz, Ricardo Marques, Marco G. Alves, et al.
Journal of Cancer Research and Clinical Oncology (2015) Vol. 142, Iss. 1, pp. 5-16
Closed Access | Times Cited: 56
Regulation of GLUT Transporters by Flavonoids in Androgen-Sensitive and -Insensitive Prostate Cancer Cells
Pedro González‐Menéndez, David Hevia, Aida Rodríguez‐García, et al.
Endocrinology (2014) Vol. 155, Iss. 9, pp. 3238-3250
Open Access | Times Cited: 54
PET nanoplastics interactions with water contaminants and their impact on human cells
Davide Magrì, Marina Veronesi, Paola Sánchez‐Moreno, et al.
Environmental Pollution (2020) Vol. 271, pp. 116262-116262
Closed Access | Times Cited: 47
GLUT1 expression in high-risk prostate cancer: correlation with 18F-FDG-PET/CT and clinical outcome
Salma Meziou, Cassandra Ringuette Goulet, Hélène Hovington, et al.
Prostate Cancer and Prostatic Diseases (2020) Vol. 23, Iss. 3, pp. 441-448
Closed Access | Times Cited: 42
The prognostic power of 18F-FDG PET/CT extends to estimating systemic treatment response duration in metastatic castration-resistant prostate cancer (mCRPC) patients
Matteo Bauckneht, Francesco Bertagna, Maria Isabella Donegani, et al.
Prostate Cancer and Prostatic Diseases (2021) Vol. 24, Iss. 4, pp. 1198-1207
Open Access | Times Cited: 34
Roles and therapeutic potential of the SLC family in prostate cancer—literature review
Yanpeng Fu, Junhao Chen, Xingcheng Zhu, et al.
BMC Urology (2025) Vol. 25, Iss. 1
Open Access
Impacts of competition and phenotypic plasticity on the viability of adaptive therapy
B. Vibishan, Paras Jain, V. K. Sharma, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2025)
Open Access
Genetic Alteration in Phosphofructokinase Family Promotes Growth of Muscle-Invasive Bladder Cancer
Chenmin Sun, Dabo Xiong, Yan Yang, et al.
The International Journal of Biological Markers (2016) Vol. 31, Iss. 3, pp. 286-293
Open Access | Times Cited: 42
Glycolysis Inhibition as a Strategy for Hepatocellular Carcinoma Treatment?
Andreia P Alves, A.C. Mamede, Marco G. Alves, et al.
Current Cancer Drug Targets (2018) Vol. 19, Iss. 1, pp. 26-40
Closed Access | Times Cited: 39
Page 1 - Next Page

Scroll to top